Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBNXNASDAQ:LIVNNASDAQ:NVCRNYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$14.43-3.5%$12.33$8.89▼$24.50$625.63MN/A481,725 shs359,902 shsLIVNLivaNova$42.79-2.8%$38.93$32.48▼$61.94$2.33B0.84651,905 shs513,422 shsNVCRNovoCure$19.37+1.0%$17.51$14.17▼$34.13$2.16B0.731.14 million shs873,347 shsWRBYWarby Parker$20.10-2.4%$17.01$12.46▼$28.68$2.10B2.011.91 million shs1.89 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics+3.60%-5.62%+36.41%-25.21%+1,494,999,900.00%LIVNLivaNova+5.11%-1.92%+18.14%+6.20%-26.14%NVCRNovoCure+3.45%+5.38%+3.68%-12.66%-17.15%WRBYWarby Parker+3.43%+0.49%+32.39%-13.38%+18.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBNXBeta BionicsN/AN/AN/AN/AN/AN/AN/AN/ALIVNLivaNova3.8203 of 5 stars4.53.00.00.03.51.71.3NVCRNovoCure3.7962 of 5 stars3.32.00.04.53.41.70.0WRBYWarby Parker3.1588 of 5 stars3.32.00.00.03.94.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBNXBeta Bionics 2.78Moderate Buy$24.8372.10% UpsideLIVNLivaNova 3.00Buy$59.2938.55% UpsideNVCRNovoCure 2.67Moderate Buy$32.8369.51% UpsideWRBYWarby Parker 2.61Moderate Buy$22.5612.25% UpsideCurrent Analyst Ratings BreakdownLatest BBNX, LIVN, WRBY, and NVCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025WRBYWarby ParkerRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$18.00 ➝ $21.005/21/2025WRBYWarby ParkerCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$17.00 ➝ $22.005/21/2025WRBYWarby ParkerStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$18.00 ➝ $21.005/21/2025WRBYWarby ParkerTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $24.005/20/2025LIVNLivaNovaWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$60.005/13/2025LIVNLivaNovaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.005/13/2025WRBYWarby ParkerUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$23.00 ➝ $20.005/9/2025WRBYWarby ParkerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.005/9/2025WRBYWarby ParkerTelsey Advisory GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $22.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBNXBeta Bionics$69.83M8.96N/AN/AN/A∞LIVNLivaNova$1.28B1.83$3.84 per share11.15$23.72 per share1.80NVCRNovoCure$621.71M3.47N/AN/A$3.39 per share5.71WRBYWarby Parker$795.09M2.64N/AN/A$3.08 per share6.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBNXBeta BionicsN/AN/A0.00∞N/AN/AN/AN/AN/ALIVNLivaNova$17.55M-$4.09101.8813.63N/A1.91%13.81%7.07%7/30/2025 (Estimated)NVCRNovoCure-$207.04M-$1.51N/AN/AN/A-25.93%-41.48%-12.74%7/24/2025 (Estimated)WRBYWarby Parker-$63.20M-$0.12N/A201.00N/A-4.39%-8.26%-4.37%8/14/2025 (Estimated)Latest BBNX, LIVN, WRBY, and NVCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025BBNXBeta Bionics-$0.51-$0.52-$0.01-$0.93N/AN/A4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million3/25/2025Q4 2024BBNXBeta Bionics-$0.42-$1.82-$1.40-$2.72$20.01 million$20.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBNXBeta BionicsN/AN/AN/AN/AN/ALIVNLivaNovaN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/AWRBYWarby ParkerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBNXBeta BionicsN/AN/AN/ALIVNLivaNova0.463.372.87NVCRNovoCure0.271.491.44WRBYWarby ParkerN/A2.472.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBNXBeta BionicsN/ALIVNLivaNova97.64%NVCRNovoCure84.61%WRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipBBNXBeta BionicsN/ALIVNLivaNova0.29%NVCRNovoCure6.29%WRBYWarby Parker26.55%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBNXBeta Bionics29443.36 millionN/AN/ALIVNLivaNova2,90054.53 million54.15 millionOptionableNVCRNovoCure1,320111.49 million101.40 millionOptionableWRBYWarby Parker3,030104.50 million74.67 millionOptionableBBNX, LIVN, WRBY, and NVCR HeadlinesRecent News About These CompaniesGoogle Is Back to Smart Glasses: This Time It Might WorkMay 28 at 2:16 PM | techopedia.comYoungme E. Moon Sells 33,073 Shares of Warby Parker Inc. (NYSE:WRBY) StockMay 28 at 4:49 AM | insidertrades.comWarby Parker Inc. (NYSE:WRBY) Shares Acquired by Two Sigma Investments LPMay 28 at 4:09 AM | marketbeat.comLoop Capital Maintains Buy Rating on Warby Parker (WRBY) StockMay 27 at 4:12 PM | insidermonkey.comWoodline Partners LP Sells 85,914 Shares of Warby Parker Inc. (NYSE:WRBY)May 27 at 4:38 AM | marketbeat.comMan Group plc Sells 18,862 Shares of Warby Parker Inc. (NYSE:WRBY)May 27 at 3:53 AM | marketbeat.comWarby Parker Inc. (NYSE:WRBY) Shares Sold by Millennium Management LLCMay 27 at 3:38 AM | marketbeat.comWarby Parker FY2026 EPS Forecast Increased by Roth CapitalMay 27 at 2:07 AM | marketbeat.comBank of America Corp DE Increases Position in Warby Parker Inc. (NYSE:WRBY)May 26 at 3:21 AM | marketbeat.comFY2026 EPS Estimate for Warby Parker Increased by AnalystMay 26 at 2:09 AM | americanbankingnews.comQ3 Earnings Estimate for Warby Parker Issued By Roth CapitalMay 25 at 8:20 AM | marketbeat.comQ3 Earnings Forecast for Warby Parker Issued By Roth CapitalMay 25 at 2:09 AM | americanbankingnews.comWarby Parker (NYSE:WRBY) Price Target Raised to $21.00May 24, 2025 | marketbeat.comCastleark Management LLC Invests $4.29 Million in Warby Parker Inc. (NYSE:WRBY)May 24, 2025 | marketbeat.comWarby Parker (NYSE:WRBY) Stock Price Expected to Rise, TD Securities Analyst SaysMay 24, 2025 | americanbankingnews.comWarby Parker (WRBY) Joins AI Race, Google Backs Smart Glasses ProjectMay 23, 2025 | insidermonkey.comWarby Parker (NYSE:WRBY) Sees Strong Trading Volume After Analyst UpgradeMay 23, 2025 | marketbeat.comWarby Parker teams with Google. Is the stock a buy?May 23, 2025 | cantechletter.comWarby Parker (NYSE:WRBY) Price Target Raised to $24.00 at TD SecuritiesMay 23, 2025 | marketbeat.com13,688 Shares in Warby Parker Inc. (NYSE:WRBY) Bought by Gotham Asset Management LLCMay 23, 2025 | marketbeat.comCitigroup Forecasts Strong Price Appreciation for Warby Parker (NYSE:WRBY) StockMay 23, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBBNX, LIVN, WRBY, and NVCR Company DescriptionsBeta Bionics NASDAQ:BBNX$14.43 -0.52 (-3.48%) As of 04:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.LivaNova NASDAQ:LIVN$42.79 -1.23 (-2.79%) Closing price 04:00 PM EasternExtended Trading$42.78 -0.01 (-0.01%) As of 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.NovoCure NASDAQ:NVCR$19.37 +0.19 (+0.99%) Closing price 04:00 PM EasternExtended Trading$19.65 +0.28 (+1.44%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Warby Parker NYSE:WRBY$20.10 -0.49 (-2.38%) Closing price 03:59 PM EasternExtended Trading$20.48 +0.38 (+1.89%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
